Abdominal aortic aneurysm (AAA) affects 5-10% of the male and females over the age of 65 and is the 13*^ leading cause of death in the United States. AAA, defined as a permanent localized dilation in the arterial wall with a diameter greater than 50% of normal, is an inflammatory disease of the aorta that can result in dissection of the wall, formation of an intramural clot, and rupture of the aorta resulting in almost immediate death in the majority of cases. Importantly, the role of the intramural clot in the etiology of AAA remains poorly explored. We will test the two specific hypotheses that formation of an intramural clot stabilizes early AAAs while conversely resulting in detrimental inflammation and protease activity in late-stage AAAs. Specifically, I will investigate the roles of tissue factor (TF), thrombin, platelets, and protease activated receptors (PARs) in the formation and progression of AAAs. We will utilize the angiotensin II (Angll) LDLr-/- mouse model of AAA. We will use both genetic and pharmacologic approaches to modulate the expression and activity of different proteins and determine the effect on AAA. My proposal is divided into four aims, the first two being mentored and the last two being independent.
Aim 1 will examine the role of platelets and the thrombin receptor on platelets (PAR-4) in AAA initiation. We hypothesize that decreased PAR-4-dependent activation on platelets or anti-platelet therapy will reduce clot formation and increase AAA rupture.
Aim 2 will examine the intervention of anti-platelet drugs on AAA progression. We hypothesize that decreased platelet activation results in less inflammation, matrix metalloproteinase activity, and subsequent rupture.
Aim 3 will determine the role of TF in Angll-induced AAA progression and rupture. We hypothesize that decreased TF coagulant activity will reduce clot formation that promotes AAA rupture, and reduced TF and PAR-2 expression by vascular smooth muscle cells (VSMCs) will result in expansion of AAAs due to reduced VSMC migration.
Aim 4 will determine the role of thrombin and the downstream effectors fibrinogen and PAR-1 in AAA. We hypothesize that fibrinogen deficiency and anticoagulant therapy will decrease clot formation and lead to an increase in AAA rupture and, that PAR-1 deficiency will increase AAA due to decreased VSMC migration. Together, these studies will increase our understanding of the role of the coagulation cascade, platelets and PARs in the initiation, progression, and rupture of AAAs. The clinical significance of this work is that use of anti-thrombotic drugs may increase or decrease the risk of AAA rupture in patients in a temporal manner.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Transition Award (R00)
Project #
5R00HL116786-05
Application #
9251316
Study Section
Special Emphasis Panel (NSS)
Program Officer
Galis, Zorina S
Project Start
2013-03-15
Project End
2018-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
5
Fiscal Year
2017
Total Cost
$241,397
Indirect Cost
$88,614
Name
University of Cincinnati
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Sundermann, Alexandra C; Saum, Keith; Conrad, Kelsey A et al. (2018) Prognostic value of D-dimer and markers of coagulation for stratification of abdominal aortic aneurysm growth. Blood Adv 2:3088-3096
Cameron, Scott J; Russell, Hannah M; Owens 3rd, A Phillip (2018) Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental? Blood 132:2619-2628
Jones, Shannon M; Mann, Adrien; Conrad, Kelsey et al. (2018) PAR2 (Protease-Activated Receptor 2) Deficiency Attenuates Atherosclerosis in Mice. Arterioscler Thromb Vasc Biol 38:1271-1282
Owens, A Phillip; Robbins, Nathan; Saum, Keith et al. (2018) Tefillin Use Induces Remote Ischemic Preconditioning Pathways in Healthy Males. Am J Physiol Heart Circ Physiol :
Saum, Keith; Campos, Begoña; Celdran-Bonafonte, Diego et al. (2018) Uremic Advanced Glycation End Products and Protein-Bound Solutes Induce Endothelial Dysfunction Through Suppression of Krüppel-Like Factor 2. J Am Heart Assoc 7:
Daugherty, Alan; Tall, Alan R; Daemen, Mat J A P et al. (2017) Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 37:e131-e157
Daugherty, Alan; Tall, Alan R; Daemen, Mat J A P et al. (2017) Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. Circ Res 121:e53-e79
Kopec, Anna K; Abrahams, Sara R; Thornton, Sherry et al. (2017) Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J Clin Invest 127:3152-3166
Rautou, Pierre-Emmanuel; Tatsumi, Kohei; Antoniak, Silvio et al. (2016) Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury. J Hepatol 64:53-9
Boulaftali, Yacine; Owens 3rd, A Phillip; Beale, Ashley et al. (2016) CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in Mice. Arterioscler Thromb Vasc Biol 36:792-9

Showing the most recent 10 out of 12 publications